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Abstract
This commentary explores the implications of increased social media marketing by drug manufacturers, 
based on findings in Hyosun Kim’s article of the major themes in recent Food and Drug Administration 
(FDA) warning letters and notices of violation regarding online direct-to-consumer promotions of 
pharmaceuticals. Kim’s rigorous analysis of FDA letters over a 10-year span highlights a relative abundance 
of regulatory action toward marketer-controlled websites and sponsored advertisements, compared to 
branded and unbranded social media messaging. However, social media marketing efforts are increasing, 
as is FDA attention to these efforts. This commentary explores recent developments and continuing 
challenges in the FDA’s attempts to provide guidance and define pharmaceutical company accountability in 
marketer-controlled and -uncontrolled claims disseminated through social media.
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The United States is one of only two countries that allow direct-to-consumer advertising of prescription drugs; pharmaceutical companies are thus particularly 
compelled to market in the United States, spending upwards 
of $4.2 billion per year targeting consumers directly.1 
In particular, online direct-to-consumer advertising of 
pharmaceuticals is an increasingly popular means for 
marketing in the United States, with expenditures estimated 
at $1.86 billion for online advertising.2 Use of social media, for 
example Facebook, Twitter, or YouTube, is increasingly a part 
of pharmaceutical companies’ marketing strategies.3 
Hyosun Kim conducted a rigorous analysis of all US Food and 
Drug Administration (FDA) warning letters and notices of 
violations issued to drug manufacturers regarding their online 
promotional activities to consumers over the 10-year period 
spanning 2005 to 2014.4 Of the 73 citations Kim analyzed, 
nearly half were in reference to a company-controlled 
webpage or website. A fourth of the letters concerned paid 
advertisements in the form of sponsored links or banner ads. 
Just two of the letters referred to social media messages, both 
of which regarded Facebook use. The common theme within 
the body of letters regarded information quality; lack of 
risk information and mischaracterized efficacy information 
were the most prevalent allegations, followed by incomplete 
product names and insufficient ingredient information. 
In general, Kim’s findings provide a modern exemplar of 
the FDA’s custom of regulating based on a comparison 
of advertising claims with medical label information.5 
Contents of the FDA warnings also corroborate concerns 
among medical practitioners and the general public about 
pharmaceutical advertising. Many physicians feel direct-to-
consumer advertisements (DTCA) lack information about 
adverse side effects, monetary cost, and alternative treatment 
options.6 The majority of laypersons are skeptical of the 
quality of information in DTCA and feel DTCA might have 
negative effects on others’ doctor-patient relationships and 
competence in their own healthcare.7 
The fact that only two letters relating to social media were 
found within this 10-year span is surprising, however, given 
the top ten pharmaceutical companies all have Facebook 
pages and Twitter feeds (many of these companies also host 
a YouTube channel).3 Arguably, this finding suggests the 
current research underestimates the prevalence of incomplete 
and incorrect information about pharmaceuticals that 
exists online. Supporting this argument, four additional 
FDA warnings related to Facebook messages were issued in 
February 2015 alone, suggesting the FDA is increasing its 
effective vigilance of social media. 
The most oft-cited allegation across the February 2015 letters 
plus the two letters Kim analyzed concerned unapproved 
claims about a drug presented by the drug manufacturer 
on its company-branded Facebook page. Kim categorized 
the two Facebook-related warnings she encountered as 
being marketer-influenced rather than marketer-controlled. 
However, the FDA has found incidents that attest to the 
presence of both marketer-controlled and marketer-
influenced claims on Facebook and other social media. 
Consider Vitalab Co., Inc., which received a warning letter 
on October 16, 2014 for making unapproved claims about 
its product, Vit-Ra-Tox, via its company-authored Facebook 
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posts. NanoBiotech Pharma received a similar warning on 
February 26, 2015 for its own Facebook posts. These incidents 
are arguably marketer-controlled, as the posts were created by 
company representatives. Therefore, responsibility for this 
primary content lies clearly with the company, and so the 
FDA may take action against the company for producing and 
disseminating the unapproved claim.
Accountability for claims are less clear when the content is 
not directly marketer-controlled, which Kim refers to as 
marketer-influenced. On December 11, 2012, AMARC 
Enterprises received a warning for endorsing, via a Facebook 
“like,” an unapproved claim about its product, Poly-MVA for 
pets, which had been posted on another company’s Facebook 
page. In this case, the origin of the claim is unclear, as it is 
not possible from viewing the claim to ascertain whether 
AMARC might have authored the content or encouraged the 
other company to create and disseminate the claim. Similarly, 
Zarbee’s, manufacturer of a natural cough remedy, received 
an FDA warning on June 27, 2014 for “liking” unapproved 
claims posted to the company’s Facebook wall by third parties 
(Zarbee’s was also warned about their Twitter posts implying 
their product was a drug rather than a dietary supplement). 
In June 2014, the FDA issued a draft report of social media 
guidelines to address third party misinformation.8,9 Relevant 
to the determination of authorship, the FDA indicated that it 
considers a company’s responsibility for a claim to increase, 
the closer the company is to the creation or endorsement 
of the claim.9 A second report focusing on Twitter was also 
issued in June 2014, indicating that a company may embed a 
direct link within a message that directs a user to additional 
information about the product.10 However, in the initial 
message and in the linked information, risk information must 
be complete and be afforded the same prominence as benefit 
information.10 Furthermore, all information and links must 
be branded.10 The overriding suggestion by the FDA in these 
reports is for pharmaceutical companies to consider avoiding 
use of the medium if there is concern of noncompliance or an 
inability to comply.8-10 
These points can most easily be evaluated and enforced when 
a message has clearly been posted by the company. However, 
as is evident in the recent body of allegations, a great deal 
of ambiguity surrounds social media, and regulators will 
likely continue to struggle with defining the company’s 
agency, and therefore responsibility, in pharmaceutical 
messages disseminated outside the company’s branded 
media channels.11 Yet, as Kim concludes, it is vital that the 
FDA increase its monitoring of social media either directly 
or through a third-party system. Health information 
continues to be one of the most frequently sought topics on 
the internet.12 In social media specifically, health information 
is widely shared; over 80% of young adults have disclosed 
health information and have sought health information at 
least once through a social media channel.13 Consumers who 
actively seek out online health information tend to believe the 
information to be credible, irrespective of whether a medical 
expert has actually authored the information.14 Unlike their 
perceptions of other methods of DTCA, consumers are less 
skeptical of online information unless they are expressly 
motivated to recognize the intent of these messages as 
persuasive.15 Thus, marketer-influenced messages, especially 
if unbranded, are particularly problematic for both consumers 
and regulators, as these messages often appear to be word-
of-mouth information offered by a fellow layperson.16 In 
fact, the message might be originating from a compensated 
blogger or brand ambassador, as was the case with celebrity 
Kim Kardashian’s paid endorsement of morning sickness 
drug, Diclegis, disseminated via Instagram post.17 Diclegis 
manufacturer, Duchesnay, Inc., received an FDA warning 
about this incident on August 7, 2015.
It is likely that the use of unbranded content by pharmaceutical 
companies will continue to grow, given that consumers tend 
to trust information from unbranded sources more than 
they trust branded sources.13 To the extent that the messages 
are either marketer-influenced or simply favorable toward a 
company product, these messages can serve as a conduit to 
attract users to the company’s branded information.11 Thus, the 
potential to drive consumers toward this branded information 
might overcome current hesitations of some pharmaceuticals 
to capitalize on third party social media messaging outside 
their marketing campaigns, despite the understanding 
that this messaging, though potentially advantageous, is 
nonetheless uncontrollable.17 Both companies and regulators 
will likely remain concerned, however, about the potential 
misinformation and encouragement of misuse (eg, off-label 
use) of a drug in user-generated social media messages, 
which can harm public health as well as company marketing 
efforts.18,19 
Perhaps more attractive to companies, Facebook and/or other 
social media offer venues for marketer-controlled, marketer-
influenced, or simply advantageous cause-related marketing 
opportunities, such that users interested in a social issue 
(eg, childhood obesity, heart disease) might be converted to 
potential consumers of a relevant product (eg, cholesterol 
lowering medication).20 Again, cause-related virtual spaces 
might or might not be formally branded and might or might 
not be managed by the pharmaceutical company. The onus 
thus falls to regulators to identify when a cause-related space 
is, in fact, a component of a company’s social media marketing 
campaign, just as regulators and companies alike will be 
challenged in determining when claims offered via messages 
outside marketer control become the responsibility of the 
company. According to the FDA’s 2014 draft guidance on 
third party misinformation, pharmaceutical companies will 
not be held responsible for user-generated content.8 However, 
as the FDA increases its guidance on how it will consider 
accountability of online messages, pharmaceutical companies 
might be increasingly tempted to leverage favorable user-
generated messages, which may further obfuscate the 
distinction between controlled and uncontrolled content.17 
A replication of Kim’s content analysis of FDA warnings ten 
years from now would be very informative in examining how 
successful the FDA becomes in detecting drug manufacturer 
accountability in online unapproved claims, assuming 
pharmaceutical companies continue the trend toward online 
and social media marketing.
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